ACGL enters the back half of August with a quietly improving setup — short sellers have pulled back sharply, analysts are nudging targets higher, and the stock is holding near $98.71 despite a softer month for the broader insurance group.
The most striking development this week is the speed of the short unwind. Short interest has dropped nearly 9% over the past week and sits at just 2.2% of the free float — a low-conviction bear position by any measure. What makes the retreat notable is the pace: shorts held roughly 8.7 million shares as recently as August 5th; that figure is now under 8 million. Borrow conditions tell the same story. Cost to borrow has fallen 33% over the week to a near-nominal 0.32%, and availability is extraordinarily loose — more than 4,100% relative to shares currently borrowed, meaning the lending pool is effectively unconstrained. This is a market where it costs almost nothing to be short and there is no squeeze pressure whatsoever. Options are similarly benign. The put/call ratio is running at 1.05, slightly below its 20-day average of 1.13 and close to its most call-friendly reading in weeks — a modest lean toward optimism rather than any defensive scramble.
The Street has spent the past month quietly upgrading its conviction on the stock, even when ratings haven't moved. Multiple firms lifted price targets in the days around the July 29 earnings print — RBC Capital, Wells Fargo, and JP Morgan all raised their numbers, with RBC and UBS sitting at $120 targets against a current price of $98.71. JP Morgan lifted its target again this week to $118, maintaining a Neutral rating but acknowledging the fundamental progress. The consensus mean target now stands at $111.87, implying roughly 13% headroom. That said, not every firm is convinced: Cantor Fitzgerald and Mizuho hold Neutral ratings with targets in the $104-$110 range, and KBW trimmed its target to $99 in early July — just barely above where the stock trades today. The valuation picture is undemanding. The trailing P/E is around 10.2x and price-to-book sits near 1.3x, both broadly flat over the past month. The EV/EBIT factor ranks in the 75th percentile, suggesting the stock is inexpensive on an earnings basis relative to the wider universe.
The bull and bear cases pulling at ACGL are straightforward. Bulls point to the reinsurance segment's decade-long growth from under $2 billion in gross written premiums to over $11 billion, rising net investment income as global yields stay elevated, and a trajectory toward book value per share near $75 by end-2027. Bears counter with a 13.5% year-on-year decline in property premiums in Q2 2025, projections for underwriting income to fall roughly 25% by 2027, and the looming pressure of social inflation on loss reserves. EPS surprise ranks in the 70th percentile — the company has a solid history of beating estimates — but forward EPS momentum is weak, ranked in the bottom quartile of the universe on both 30-day and 90-day measures. The ORTEX short score has drifted modestly lower this week to 34.9, consistent with a stock where short-side pressure is fading rather than building.
The most recent earnings print on July 29 produced a one-day decline of 5%, with the stock then losing a further 2% over the following five sessions — a pattern worth tracking given the next event is on the calendar for October 29. Peers offered limited help this week: CB fell 1.9% and HIG dropped 3.7%, while RNR and AFG managed small gains of around 0.5%. ACGL's near-flat week — up just 0.2% — looks relatively resilient in that context.
The next test is whether analysts raising targets translates into price momentum ahead of October earnings, or whether the property premium headwinds and forward earnings revisions keep a ceiling on the stock at levels just below where the cautious neutral-rated firms have drawn the line.
See the live data behind this article on ORTEX.
Open ACGL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
